Elevance Health(ELV) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Adjusted diluted earnings per share for Q4 2025 was $3.33, and for the full year, it was $30.29, benefiting from greater tax favorability than anticipated [16] - Operating revenue for Q4 totaled $49.3 billion, a 10% increase from the prior year, driven by premium rate adjustments and acquisitions [17] - Consolidated benefit expense ratio was 93.5% for Q4 and 90% for the full year, in line with guidance [17] - Adjusted operating expense ratio was 10.8% for Q4 and 10.5% for the full year, reflecting disciplined management [18] Business Line Data and Key Metrics Changes - Medicaid operating margin expected to be approximately -1.75% in 2026, with improvement anticipated over time [6][19] - Medicare Advantage membership expected to decline in the high teens percentage range in 2026, reflecting deliberate portfolio actions [8][20] - Commercial business showed healthy momentum, particularly in national accounts, supported by a productive selling season [9] Market Data and Key Metrics Changes - Membership decreased to 45.2 million, a decline of approximately 500,000 year-over-year, primarily due to Medicaid membership loss [17] - Individual ACA market repositioned to reflect higher costs and the expiration of enhanced subsidies, maintaining value for consumers [8] Company Strategy and Development Direction - 2026 is viewed as a year of execution and repositioning, with a focus on improving outcomes and managing costs [5][10] - The company aims for at least 12% adjusted EPS growth in 2027, supported by diversified platform earnings power [6][14] - Long-term enterprise margin target is set at 5%-6%, with health benefits targeting mid-single-digit margins [10][24] Management's Comments on Operating Environment and Future Outlook - Management acknowledges affordability as a central challenge in healthcare and emphasizes the importance of care coordination and reducing complexity [5] - The company is confident in its long-term algorithm and expects to return to at least 12% adjusted EPS growth in 2027 [14][23] - Management is actively engaging with state partners to address Medicaid program sustainability amid changing eligibility requirements [7][50] Other Important Information - Operating cash flow was $4.3 billion for the year, with expectations of at least $5.5 billion for 2026 [21] - The company repurchased 1.4 million shares for $470 million in Q4, totaling $2.6 billion for the year [21] Q&A Session Summary Question: Cost trend across major lines of business - Management expects cost patterns in commercial to remain stable, with elevated trends in ACA due to subsidy expirations [27][28] Question: Membership declines during AEP - Membership declines were aligned with margin-focused strategies, with a focus on D-SNP and HMO products [33][36] Question: Medicaid margin drivers - Medicaid margins were slightly better than expected due to favorable prior period developments and modest retroactive rates [41][42] Question: Capital deployment priorities - Near-term capital allocation will focus on maintaining a strong credit profile and funding targeted investments [78][80] Question: Confidence in long-term EPS growth - Confidence in 12%+ EPS growth is based on prudent 2026 outlook and actions already underway to improve margins [55][57]